Early win: Novartis wards off Indian Galvus contender

Novartis has managed to ward off an Indian generic challenger in a case concerning its DPP-4 inhibitor for diabetes, vildagliptin, with the latter undertaking not to manufacture the product or its combination until the product's patent is valid in India.